Clinical–pharmacogenetic predictive models for MTX discontinuation due to adverse events in rheumatoid arthritis
Crossref DOI link: https://doi.org/10.1038/tpj.2016.36
Published Online: 2016-05-24
Published Print: 2017-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Jenko, B
Lusa, L
Tomsic, M
Praprotnik, S
Dolzan, V
Text and Data Mining valid from 2016-05-24
Version of Record valid from 2016-05-24
Article History
Received: 3 November 2015
Revised: 4 February 2016
Accepted: 15 April 2016
First Online: 24 May 2016
Competing interests
: The authors declare no conflict of interest.